<scp>P53</scp> immunolabeling in <scp>EUS‐FNA</scp> biopsy can predict low resection rate and early recurrence in resectable or borderline resectable pancreatic cancer treated with neoadjuvant therapy
Journal of hepato-biliary-pancreatic sciences